Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial - Brose, MS; Robinson, B; Scherman, SI (Lancet Oncol, 2021)
et al.